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Abstract
Hypopharyngeal carcinoma is uncommon in all head and neck cancers. With 
a synergistic reaction of each, tobacco consumption and alcohol abuse contribute 
to the tumorigenesis. The aerodigestive tract epithelium exposure to similar risks 
causing multiple cancers. Thus, a pan-endoscopic screening offers a practical 
approach for evaluating second primary esophageal cancer. The common symptoms 
of hypopharyngeal carcinoma were globus pharyngeus, sore throat, dysphagia, 
otalgia, neck mass, hoarseness, and dyspnoea. However, approximately 75–80% 
of patients are initial diagnosed with advanced-stage. Although improvements 
in therapy, the prognosis is still lacking. In early-stage patients, primary surgical 
resection and radiotherapy achieved similar survival and locoregional control rates. 
T1–T2 malignancies with N0–N1 can usually be treated with radiation alone, open 
surgery, or transoral surgery. In some people, after primary surgery or transoral 
approaches is often required adjuvant radiotherapy. However, most cases have 
been in the advanced-stage when screened. Individual therapy programs should be 
chosen carefully to achieve a balance between swallowing-voice rehabilitation and 
organ preservation in advanced-stage ones. Meanwhile, reasonable reconstruction 
of intraoperative defect is essential for a surgeon who seeks satisfied postoperative 
outcomes. Considerable treatment (surgery or non-surgery) remains the key point 
of improving the survival rate.
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1. Introduction
Hypopharyngeal carcinoma is relatively rare in all head and neck cancers 
(approximately 3–5%) [1, 2]. The overall worldwide age-standardized incidence 
rates occur at a rate of 0.8 per 100,000 (1.4 in men and 0.3 in women) in hypo-
pharyngeal cancer [3]. Bangladesh had the highest incidence with 4.8 per 100,000 
[4]. In the past four decades, the incidence of hypopharyngeal cancer has declined 
smoothly in America, in part due to decreasing intake of tobacco [5–7]. Overall, it 
is five times greater in males than in females [8] and mainly occurs in the aged 50 to 
70 years [5, 9]. However, this tumor rarely occurs at young ages [10].
Epidemiologic studies showed a series of potential environmental risk fac-
tors for hypopharyngeal carcinoma development. Tobacco consumption (> 90% 
of patients) and alcohol abuse (> 70% of patients) are the two well-established 
risk factors for hypopharyngeal squamous cell carcinoma [11–13]. Heinz Maier 
et al. reported a time-response correlation between tobacco intake and hypo-
pharyngeal cancer. Besides, the amount of alcohol consumption is also related to 
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cancer development. Compared to non-smokers, it increased the risk by 9.5-fold 
(adjusted for alcohol consumption) for the long-term smoker (40–60 tobacco 
years). Also, alcohol drinkers increased the risk of this cancer that was up to 
125.2-fold (adjusted for tobacco consumption) for alcoholics (> 100 g/day) [13]. 
Moreover, there is a synergistic carcinogenic effect between tobacco use and 
alcohol abuse [14]. Quitting smoking and refrain from drinking may reduce the 
risks of hypopharyngeal cancer.
Other risk factors, such as nutritional factors, diet, Plummer-Vinson syndrome, 
gastroesophageal reflux disease [15], and chronic infectious diseases have been 
reported to increase the risk of hypopharyngeal tumor. An inadequate caloric intake 
may lead to cancer cachexia, associated with a poor prognosis for hypopharyngeal 
carcinoma [16]. Plummer-Vinson syndrome is responsible for post-cricoid carci-
noma, characterized by dysphagia and iron deficiency anemia. [17, 18]. It has been 
reported that oncogenic viral infection has a close relationship with head and neck 
cancers. The human papillomavirus (HPV) is involved in the malignant transforma-
tion of oropharyngeal carcinoma [7]. Epstein–Barr virus (EBV) infection is relevant 
to nasopharyngeal carcinoma (NPC) tumorigenesis [19]. Nevertheless, HPV and 
EBV infection in hypopharyngeal cancer are rare [20–22]. To date, the possible role 
of HPV in tumorigenesis of hypopharyngeal cancer is still controversial, EBV as 
well [23, 24].
In hypopharyngeal cancer, most histological types are squamous cell carci-
noma (SCC) (up to 95%). That is usually represented poorly differentiated [25]. 
Adenocarcinoma is less frequent than in hypopharyngeal malignancies, accounted 
for around 5%. Other rare malignant tumors: papillary (exophytic) squamous cell 
carcinoma, verrucous carcinoma, and lymphoepithelial-like carcinoma, have been 
reported. However, the non-epithelial neoplasms that may arise in the hypopharynx 
include mucosal malignant melanoma, synovial sarcoma, fibrosarcoma, and lipo-
sarcoma, are not included [26]. Both histologic confirmations and histopathologic 
grading of squamous carcinoma should be recorded in hypopharyngeal cancers.
2. Symptoms and diagnosis
2.1 Relevant anatomy of hypopharynx
There are three parts to the pharynx: nasopharynx, oropharynx, and hypophar-
ynx. As part of the pharynx, the hypopharynx is located behind the entire length 
of the larynx. It extends from the plane of the epiglottis to the lower border of the 
cricoid cartilage. Moreover, the pharynx is further classified into three regions 
(Figure 1): (1) the piriform sinuses, (2) the posterior pharyngeal wall, and (3) the 
post-cricoid area.
The pyriform sinus, a bilateral area, is bounded by the aryepiglottic fold and 
laterally by the esophagus’s upper end. The posterior pharyngeal wall is bounded 
from the superior level of the epiglottis to the lower border of the cricoid cartilage 
and from the vertex of one pyriform sinus to the other. The post-cricoid region lies 
on the arytenoid cartilages’ level and connecting to the plane of the inferior border 
of the cricoid cartilage.
In general, hypopharyngeal cancer occurs most in the piriform sinuses in 
60–85% of patients, followed by the posterior pharyngeal wall up to 10–20% and 
rarely in the post-cricoid area in 5–15% of patients (Figure 2) [9, 27]. Also, dur-
ing these three hypopharyngeal subsites, the tumor of the pyriform sinus and the 
posterior pharyngeal wall is mainly in males, while post-cricoid carcinoma is more 
often occurs in females [5, 9].
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2.2 Symptoms and signs of hypopharyngeal carcinoma
Early in hypopharyngeal cancer is not easy to be found due to the asymptomatic 
for an extended period. Something sticking or irritative sensation in the throat 
could be the early symptoms. If the tumor increases to a considerable size, sore 
throat, increasing dysphagia, and referred otalgia on swallowing may be present. 
Besides, progressive dysphagia frequently leads to significant weight loss.
A neck mass is now recognized as the typical clinical manifestation of hypopha-
ryngeal carcinoma. There are a rich lymphatic network and vascular anatomy in the 
neck, allowing tumors to easily metastasize to the cervical nodal. Clinically, more 
than half of patients have enlarged cervical nodes at initial presentation because of 
the vibrant lymph nodes network in the pharynx [28]. The neck metastases rate is 
higher (> 75% of patients) in pyriform sinus cancers, as compared with the neck 
metastases rate in the posterior pharyngeal wall and post-cricoid cancers [29, 30]. 
Lymphatics from pyriform sinuses usually result in levels II-III and retropharyngeal 
node metastasis. And the posterior pharyngeal wall lymphatic metastasis area is 
more occurred to level II lymph node metastasis. In contrast, lymph node metastasis 
of the post-cricoid region prefers to levels IV-VI metastasis [31–33].
The larynx functions mainly in airway protection and respiration, which is in 
front of the hypopharynx. The hypopharynx configuration may allow tumor inva-
sion or involvement of these adjacent organs, for instance, the larynx. When the 
throat symptoms appear, the tumor is considered significant in particular hoarse-
ness, invading the larynx. Furthermore, some of the patients may present aggres-
sive laryngeal invasion with life-threatening airway obstruction.
2.3 Second primary cancer
Patients with hypopharyngeal cancer have an exceptionally high risk of 
diagnosing a synchronous or metachronous second primary cancer, which may 
be associated with the prognosis’s deterioration [34]. One possible mechanism 
causing second primary cancer in hypopharyngeal cancer is the phenomenon 
of “field cancerization” [35]. Anatomically, the cervical esophagus is originated 
at the upper esophageal sphincter, contiguous with the post-cricoid region 
Figure 1. 
Anatomical subsites of hypopharynx. (A) The pharynx includes three parts: The nasopharynx, oropharynx, 
and hypopharynx. (B) The hypopharynx is situated posterior to the larynx. It is further subdivided into the 
pyriform sinuses (left and right), posterior pharyngeal wall, and post-cricoid area.
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and behind the lower border of the cricoid cartilage. The aerodigestive tract 
mucosa, including hypopharynx and esophagus epithelium, is the squamous 
epithelium. During the carcinogenesis process, both hypopharynx epithelium 
and esophagus epithelium are exposed to similar environmental risk factors 
resulting in multiple cancers in the aerodigestive tract [35–37]. Tobacco use 
and alcohol abuse are considered as the significant risks contributing to field 
cancerization.
In head and neck cancers, the overall incidence of the synchronous second 
primary cancer was estimated to be 12% [38]. However, hypopharyngeal 
cancer has a high incidence of second primary cancer. The commonest sites in 
Figure 2. 
Typical subtypes of hypopharyngeal carcinoma. (A, D) The pyriform sinus carcinoma (left) (red arrow) 
involving the left side of aryepiglottic fold in endoscopy (A) and (D) CT scan. (B, E) The posterior pharyngeal 
wall carcinoma (red arrow) in endoscopy (B) and (E) CT scan. (C, F) The hypopharyngeal carcinoma 
(red arrow) arising from the post-cricoid region in endoscopy (C) and (F) CT scan. (G) The patterns of 
hypopharyngeal carcinoma. (H) The percentages of hypopharyngeal carcinoma in three subtypes.
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the second primary cancer [39] were the esophagus (27%) and lung (6.34%) 
[40–42]. Therefore, patients with hypopharyngeal carcinoma are suggested 
to undergo regular surveillance endoscopy (Figure 3) and chest CT scan to 
detect a second malignancy. Precancerous lesions or neoplasm are the targets of 
surveillance endoscopy. In case of suspected neoplasm, an endoscopic biopsy 
can be done to diagnose second primary esophageal cancer. The use of narrow-
band imaging (NBI) shows high accuracy to screen early esophageal lesions, 
Lugol chromoendoscopy (LCE) endoscopy as well [43]. Most of the second 
primary cancer followed the hypopharyngeal cancer diagnosis within one 
year [34, 40].
2.4 Diagnostics of Hypopharyngeal carcinoma
2.4.1 History and physical examination
To assess the patient’s condition, a thorough history of presenting symptoms 
must be obtained. It also is crucial to document and quantification of tobacco or 
alcohol use history. And then, a complete head and neck examination should be 
performed. Neoplasm and its extent can often be seen on indirect or laryngoscopy 
Figure 3. 
The second primary cancer in hypopharyngeal cancer. (A, B) Hypopharyngeal cancer involving pyriform 
sinus (red arrow) by endoscopy and CT scan, respectively. (C, D) Second primary esophageal cancer of 
hypopharyngeal cancer, imaged with (C) white light endoscopy; (D) narrow-band imaging.
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tests. While the post-cricoid growths may difficult to diagnose on the laryngoscopy. 
The pooling of secretions in the pyriform sinus is indicated to cervical esophageal 
involvement. Both sides of the neck should be examined to evaluate cervical lymph 
nodes, and the level, number, size, and mobility of palpable lymph nodes should be 
carefully documented.
2.4.2 Endoscopic evaluation and pathology diagnosis
In early cases, endoscopy of the laryngopharynx is best performed in the patient 
under suspicion of malignancy. The panendoscopy can evaluate the entire scope 
of cancer and find a synchronous primary at any other site. A biopsy can be done 
under general anesthesia with endoscopes. It is essential for histological typing. 
Since lymphonodi cervical metastasis often occurs as the first symptom, a fine-
needle aspiration (FNA) in the neck is recommended.
2.4.3 Imaging studies
Nowadays, the application of imaging measurement offers an efficient approach 
for evaluating the tumor extent, lymph nodal staging, potential laryngeal impinge-
ment, and cartilage involvement. A CT enhanced scan of the laryngopharynx and 
neck is exceptionally worthy in evaluating laryngeal cartilage invasion. At the same 
time, MRI is better for the soft-tissue extension. They are complementary examina-
tions of each other and reveal the tumor invasive range. Due to the distant metas-
tasis (approximately 6% of patients) in hypopharyngeal cancer, a chest CT scan or 
PET/CT is also recommended [44].
3. Cancer staging and prognosis
The newly updated TNM classification system (8th edition), an anatomic-
based classification, was published in 2017 by The American Joint Committee 
on Cancer (AJCC). This cancer stage classification aims to provide information 
for the clinical trial, cancer control activity, therapy selection, and outcome. 
Compared to the previous version, the new vision reflects a better understand-
ing of cancer therapy and research design. Here we showed an overview of 
modifications in cancers of pharynx: (1) the revision of TNM classifications 
in nasopharyngeal cancer; (2) the division of pharyngeal malignancies into 
HPV-related (p16+) oropharyngeal cancer, oropharynx (p16-) and hypophar-
ynx cancer, and nasopharyngeal cancer; (3) the extranodal extension (ENE) 
is formulated into the N category for non-viral related head and neck cancer 
for the first time [45]. Besides, the TNM staging of hypopharyngeal cancer is 
delineated in Figures 4 and 5.
Generally, the cancer of hypopharynx has an abysmal prognosis in all head and 
neck cancers. Numerous patients (75–80%) are advanced-stage ones (stage III/IV) 
when initially diagnosed [46, 47]. About 60–75% of patients with cervical lymph 
node metastasis (N1–3) were detected [46, 47].
A population-based study reported that the five-year overall survival (OS) 
rate increased from 37.5% (1973–1989) to 41.3% (1990–2003) [9]. Also, Henry T. 
Hoffman, etc., showed the five-year disease-specific survival segregated into clini-
cal stages increased: 63.1% (stage I), 67.6% (stage II), 41.8% (stage III), and 22% 
(stage IV), respectively [48]. Although the treatments have improved, the tumor 
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recurrence within one year and half of first recurrences with distance metastases 
[1]. Unfortunately, about 50% of the untreated cancer patients surviving within 
four months after the initial diagnosis, and less than 20% of patients surviving 
more than one year [49, 50].
Figure 4. 
TNM classification of hypopharyngeal cancer. The TNM staging system is the common language for classifying 
the extent of spread of cancer. Here we reveal the newest edition in hypopharyngeal carcinoma.
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4. Treatment
Different treatment strategies, surgery, and nonoperative treatment were 
adopted according to the scope of the tumor. However, the existing literature has 
limitations due to the shortage of multicenter large sample randomized controlled 
tests. In the setting of unbalanced development in economic, academic, and medi-
cal conditions in different regions, remain in the effect of treatment, it is difficult 
to unify the mode of diagnosis and treatment, and the differences are present in 
curative effects. The general principle is to improve the postoperative life quality 
for patients on the premise of ensuring that the tumor is removed completely. 
Treatment selection requires optimizing swallowing and speaking functions to 
prevent a long-term aspiration and tracheostomy/G- tube dependence and acquire a 
balance between disease cure and anatomical preservation of tissue [19, 51].
In addition to taking effective measures to accurately determine the scope and 
clinical stage of the tumor, multidisciplinary treatment (MDT) should also run 
through the whole process of tumor diagnosis, treatment, and rehabilitation to gain 
optimal rehabilitation effect.
4.1 Early-stage tumor (T1/T2 with N0/N1)
4.1.1 Primary radiotherapy or open surgical procedures
Refinement in technology has improved radiation oncology across the past 
20 years. The newer “more precise” techniques, such as intensity-modulated 
radiotherapy, compared with standard therapy, ameliorate locoregional control 
of hypopharyngeal carcinoma [52–54]. These techniques extend the concentra-
tion of dose to the primary tumor and concomitantly lower collateral injuries to 
normal tissues [53]. The results of the retrospective analysis showed the similarity 
between the long-term survival prognosis of primary radiotherapy and laryngec-
tomy [55–57]. However, prospective evidence is limited for the similarity between 
locoregional control and survival rates [46, 58, 59]. Postradiation local control rate 
was achieved in 68–90% of patients with T1 tumors and approximately 75% cases 
in T2 lesions [58, 60–62]. The goal of radiation with concurrent chemotherapy is to 
acquire speaking and swallowing functional of invaded area and laryngeal preser-
vation rates for five years above 70% [52, 63, 64]. Radical radiation-related injuries 
to the neck tissues need to be taken seriously, including substantial acute and late 
Figure 5. 
Prognostic stage of hypopharyngeal cancer.
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toxicity (Figure 6). Although a majority of acute toxicities are temporary (such as 
radiation-related dermatitis usually alleviated within 6–12 weeks of treatment), 
permanent xerostomia at least partly is present invariably. Post-radiotherapy 
complications such as aspiration and chronic dysphagia may also occur in some 
cases, depending on the permanent feeding tube. The incidence is growing associ-
ated with intensive protocols (e.g., concurrent chemoradiotherapy). Therefore, 
effective quality assurance mechanisms and appropriate expertise are needed to be 
established to limit treatment-related toxicity and optimize results.
The skin injury often occurs during radiotherapy, including red swollen of skin, 
painful blisters, and pigmentation.
Open surgery is also an available approach for early-stage lesions compared 
with radiotherapy [65]. The posterior pharynx tumors can be excised through the 
transhyoid approach [66, 67]. Meanwhile, reservation of the internal branch of  
the superior laryngeal nerve is necessary. The transhyoid approach is critical for the 
disease that cannot be exposed transorally, especially in advanced tumors [51].  
The more noticeable problem is that the postoperative T1T2 diseases with high-risk 
factors (e.g., positive margins, positive lymph nodes, extracapsular tumor  
extension) and locally advanced tumors should perform radiotherapy [68].
4.1.2 Transoral approaches
For T1/T2 tumor, minimally invasive surgery with reducing morbidity has become 
a surgical option for patients. In addition to open surgery, a variety of transoral surgi-
cal techniques/instrumentation, such as laser, plasma, oral robot surgery, and so on, 
setting primary tumor resection as a rising feasible option, with preserving laryngeal 
function [69, 70]. Transoral surgery (TORS/TLM) are considered as promising alterna-
tives with better functional consequence compared with open surgery. It presents fewer 
complications than open surgery with nasogastric tube dependence down from 31–3% 
within 1 year [71]. Supporters of surgery pose that the transoral method rise the laryn-
geal conservation rate by over 70% through lots of single-institution series [72, 73].
Figure 6. 
Radiotherapy toxicity of neck.
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Over the past few decades, with growing prevalence in a transoral path for 
getting into the upper aerodigestive tract, especially transoral laser surgery (TOLS), 
which initially was used for cancer of the larynx, gradually spread to the hypo-
pharyngeal tumor [72–76]. Local control and cancer-free survival rates via radio-
therapy and open surgery inT1/T2 diseases have been achieved through transoral 
routes, especially in early-stage lesions [72, 77–80]. The procedural complications 
of TOLS include fistula, granulation tissue formation, and fatal bleeding. [77–80]. 
But, in other TOLS series reported, 83% of patients were received adjuvant treat-
ment (radiotherapy or concurrent chemoradiotherapy) after TOLS according to 
pathologic outcomes [77–80]. In T3, T4 cases, because of the limitation of detailed 
data about the use of TOLS for these lesions, the potential effects (if any) of TOLS 
remains poorly explained [78, 79]. Transoral robotic surgery has been considered a 
valid treatment for early hypopharyngeal carcinoma [81–83]. Meanwhile, it is also 
regarded as more appropriate for early cases without adjuvant treatment [81].
The complete resection of the tumor should be taken as the premise, with the 
corresponding bilateral neck dissection, combining with intraoperative frozen 
section examination to achieve radical procedures. If the postoperative pathologi-
cal or histological examination indicates high-risk factors, postoperative adjuvant 
radiotherapy is required.
4.2 Advanced-stage tumor (T3/T4 or ≥ N2)
4.2.1 Non-surgical management
For the need of larynx-preservation, non-surgical treatments are considered 
as valid notions involved when appropriate [84]. At present, the non-operative 
treatment of larynx reservation is mainly combined with radiotherapy and che-
motherapy (such as simultaneous radiotherapy and chemotherapy, induction 
chemotherapy sequential radiotherapy). Targeted therapy and immunotherapy 
are still being explored. The advanced patients involved postoperative adjuvant 
radiotherapy acquired improvement of local control, cancer-free survival rate, and 
overall survival [60, 85–88].
For stage IV malignancy, chemotherapy (induction therapy or concomitant 
therapy) heightens therapeutic efficacy, which is better in locoregional control and 
survival rates than radiation alone and combination therapies (surgery + radiation 
[84, 89–92]. A randomized trial including 202 cases indicated that chemotherapy 
group (induction chemotherapy +radiotherapy) achieve almost same disease 
survival as immediate surgery, with13.1% (the chemotherapy group) versus 13.8% 
(the surgery group) in a 10-year overall survival rate and with 8.5% versus 10.8% 
in10-year progression-free survival rates [93]. For optimizing chemotherapeutic 
effectiveness, organ-preservation strategies have to be abandoned in some advanced 
diseases in order to optimize chemotherapeutic effectiveness [94]. Pretreatment 
organ dysfunction, e.g., status vocal cord fixation and tracheostomy dependence, 
are related to posttreatment poor functional outcomes [95].
When considering organ-preservation strategy, the therapeutics must be 
implemented not only for saving of the anatomical units but also the return of 
upper aerodigestive function [96–98]. Meanwhile, the advanced patients with 
extensive invasion of surrounding tissue and serious decline of pharynx and larynx 
function present low pathologic complete response by non-operative treatment. 
The opinions of various disciplines should be integrated into decision-making. 
The American Society of Clinical Oncology (ASCO) guidelines recommend total 
laryngectomy for T3/T4patients with heavy tumor load and poor laryngeal function 
before induction chemotherapy [99].
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4.2.2 Surgery
Surgery remains the preferred treatment for advanced-stage hypopharyngeal 
cancers [100]. Kinds of surgical manners are achieved in locally advanced cancers. 
Considering the possibility of aspiration after laryngeal preservation surgery, 
assessment of preoperative lung function is necessary. The cut margins (inferior or 
esophageal margin) must be extended carefully for safe boundaries. [25, 101, 102]. 
We should pay more attention to the extent of surgical margins, especially the infe-
rior margin of the tumor (nearly to the esophageal part). Wide margins surgically 
are often considering in the skip disease and submucosal positive pathology. But 
researches have shown that patients did not benefit from extended edges (3–5 cm) 
compared with traditional (1–1.5 cm) incisal edges [103].
Partial pharyngectomy integrated with a partial laryngectomy, e.g.: vertical 
hemilaryngectomy, supraglottic laryngectomy, or supracricoid laryngectomy etc. 
is utilized in a series of hypopharyngeal cancers for hypopharyngeal cancers with 
small to medium lesions [104–107]. Laccourreye et share their extensive experi-
ence with the methods described above in their researches, including 135 cases 
with pyriform fossa lesions [104, 105]. The patients were executed supracricoid 
hemilaryngopharyngectomy combined with postoperative induction chemotherapy 
(IC) (96%). Five-year actuarial survival rates were assessed at 46.7%, with trache-
ostomy tubes removed in all patients (average = 9 days), and a 91.9% recovering 
oral intake (gastrostomy-free) at one year [105]. The conservation of competing 
cricoarytenoid units is important to achieve good functional outcomes. The unit 
comprises a single arytenoid, cricoid cartilage, ipsilateral recurrent/superior laryn-
geal nerves, and ipsilateral intrinsic laryngeal muscles. At least a single company 
should be reserved to obtain suitable swallowing function and upper respiratory 
 function [108].
Due to roughly 10% of lesions invade the thyroid parenchyma directly, the cases 
with macroscopic cancer extension outside the larynx should be performed thyroid 
lobectomy or total thyroidectomy. In salvage treatments, considering thyroid 
vessel damages in response to radiation, preoperative hypothyroidism screening 
(routine pre- and post-operative thyroid hormone screening) is often necessary 
[109, 110]. In a prospective study including 137 laryngeal/hypopharyngeal patients, 
the incidence of hypothyroidism after treatment for laryngeal or hypopharyngeal 
tumors is 47.7%, especially after combination treatment [110]. Hypoparathyroidism 
is an important consideration in treatment, so the reservation or reimplantation of 
parathyroid glands must be noted during cricopharyngeal resection and/or paratra-
cheal + mediastinal lymph node dissection [103].
4.2.3 Reconstruction
Laryngopharyngeal defect reconstruction is also an important approach for 
the surgeon to optimize surgery. The reconstruction presents a certain advantage 
in reducing the incidence of postoperative complications such as pharyngeal 
fistula, fatal bleeding, or infection. Meanwhile, it shows satisfactory outcomes 
in rehabilitating functions of speaking, swallowing, and breathing. The methods 
include local issue, regional flap or more vascularized free tissue transfer (Figure 
7). Regional flaps contain the submental island flap, the supraclavicular island flap, 
the deltopectoral flap, the pectoralis, myocutaneous flap or latissimus dorsi myo-
cutaneous flaps. Vascularized free tissue transfer methods include radial forearm 
free flap, anterolateral thigh free flap. In partial pharyngectomy with a partial 
laryngectomy, the small defects are repaired by local closure, and the larger defects 
(> 3 cm in size), regional flaps, and free tissue transfer are recommended. For 
Pharynx - Diagnosis and Treatment
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partial pharyngeal defects with a total laryngectomy, despite other options, such as 
primary closure, primary closure with bolster flap, and regional tissue transfer, free 
tissue transfer has become one of the most utilized reconstructive selections. The 
major advantages of free tissue transfer are donor-site tissue, healthy tissue to repair 
circumferential defects. It is reconstructed in a tubular shape to provide a good 
swallowing tract and low incidence by avoiding entrance to other body cavities for 
total laryngopharyngectomy defects is usually rebuilt by the approaches such as 
enteric flap transposition, gastric pull-up, colonic Interposition, or jejunal free flap.
4.3 Nodal metastases in neck
Almost all patients with hypopharyngeal carcinoma have a high incidence of 
lymph node metastasis in the neck [30, 111]. Pyriform fossa cancer has the high-
est cervical metastasis rate (> 75%), while the lymph node metastasis rate of the 
posterior pharyngeal wall and posterior ring carcinoma is currently between 30% 
and 60% [29, 30, 111, 112]. For clinically negative (cN0) neck, the high-risk lymph 
node group must be included in the scope of dissection. Bilateral neck dissection 
should be considered with the tumor across the midline and tumors located in the 
Figure 7. 
Surgical reconstruction of hypopharyngeal cancer involving the larynx and esophageal. (A) The tubular gastric 
reconstruction was applied to repair the esophagus by video-assisted thoracoscopic surgery (VATS). (B, C) Inset 
of the gastric tube into the operative cavity of total laryngopharyngectomy.
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posterior pharyngeal wall, medial Pyriform wall, or posterior annular region [96, 
111]. In the cN0 cases, most of the lymph nodes with positive pathological exami-
nation were located in levels II and III of the lateral neck [46, 111, 113, 114]. Thus 
levels II to IV should be taken into consideration for elective neck dissection in the 
CN+ patients, despite the low incidence of metastases at levels I and V, the cutting 
of levels I through V is incorporated into an overall neck dissection for reducing 
relapses in a node. The internal jugular vein (IJV), sternocleidomastoid muscle, 
and accessory nerve are recommended to be preserved and attacked directly 
by cancer.
Paratracheal (level VI) and retropharyngeal nodes must be brought to attention 
because of The risk of tumor invasion [46, 115]. Paratracheal positive nodes (level 
VI) are frequently involved by tumors located in the pyriform apex or post-cricoid 
area [111, 116–119]. A series of reports by Chung et al. poses a 27.9% occult metas-
tasis rate in IV nodes with a much worse prognosis (26% vs. 55% 5-year disease-
specific survival) [119]. So paratracheal node dissection should be strongly involved 
in this crowd both for the thoroughness of removing all tumor and strict disease 
staging. The retropharyngeal nodal disease is common in lateral pyriform and 
posterior pharyngeal, existing in 40% of advanced patients [120]. Retropharyngeal 
nodes should be taken into adjuvant radiotherapy in the setting of unremovable 
surgically. In advanced stages, these positive nodes clinically/radiographically may 
be an indication for non-surgical treatment [120].
5. Surveillance, and recurrent
Due to most tumors relapse within two years after initiate treatment, rigorous 
surveillance should be followed three months after treatment until two years 
and every six months for 3–5 years to screen early local recurrence and second 
primary tumors [121–123]. A favorable scanning should involve a combination 
of history, physical, endoscope, images (CT, MRI, PET/CT), and biopsy [124]. 
For suspicion cases, repeated biopsies are necessary for positive results. PET/CT 
has been demonstrated to be more accurate than CT/MRI for screening false-
positive results [125, 126]. Surgery is considered an optimal option for recurrent 
cases (especially small recurrent). For unresectable recurrence or metastatic, 
re-irradiation or re-irradiation+chemo is one selection with improving median 
survival. Meanwhile, related toxicities cannot be ignored, with complications 
range from 9 to 32% in adjuvant chemotherapy cases [127, 128]. Therefore, the 
multidisciplinary team must seek a balance between the serious toxic reactions 
and the rescue therapy while paying attention to the progress of the disease in the 
long term.
There are not many options available for recurrent and metastasis, so it is urgent 
to develop new targeted agents in this population. The innovative drugs may be 
proved as another promising avenue for recurrence and metastasis. A variety of 
molecular targeting drugs are developed in the exploratory stage. These drugs have 
anti-cancer affection on aberrantly expressed intracellular proteins. In recent years, 
immunotherapy has been proved to ameliorate overall survival over standard, 
single-agent therapy for platinum-refractory cases [129, 130]. Anti-programmed 
cell death 1 (PD-1) therapies were assessed as a treatment for platinum-refractory 
recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). 
Meanwhile, a small number of patients with the PD-1 approach acquire lower toxic 
effects than traditional therapies. Immunotherapy brings hope to this subtype of 
treat-limited patients [130, 131].
Pharynx - Diagnosis and Treatment
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6. Conclusion
The primary type of hypopharyngeal cancer is squamous cell carcinoma, with 
a poor prognosis. Approximately up to a third of patients are diagnosed with 
second primary esophageal cancer. The infrequent incidence of hypopharyngeal 
cancer limits the extensive clinical trial application. Early-stage disease achieved 
successful tumor management after treatment (radiation alone or surgery resec-
tion). However, despite the improvements of therapy, measures alone may not be 
sufficient to preserve the laryngeal function in advanced-stage ones. Formulating 
an accurate and useful treatment plan depends on a comprehensive assessment of 
the patient’s general condition and tumor staging before treatment. To explore a 
functional tumor remission and improve survival outcomes, researchers are seeking 
a balance between swallowing-voice rehabilitation and organ preservation. Also, 
the treatment requires cooperation involved specialized expertise and a multi-dis-
ciplinary team to benefit patients. Future directions will focus on refining surgery 
to afford functional organ preservation and radiotherapy techniques. Furthermore, 
it is important to regard to influence patient outcomes; there also needs to be more 
emphasis on non-surgery therapy’s toxicity.
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